U.S. Trade Distributors Stock News

NasdaqGS:FSLR
NasdaqGS:FSLRSemiconductor

Is It Too Late To Consider First Solar (FSLR) After Its Strong Multi Year Run

If you are wondering whether First Solar at around US$214.57 is still good value after its strong run, this article walks through what the current price actually reflects. The stock has moved 6.3% over the last 7 days, 11.6% over 30 days, 60.4% over 1 year and 208.4% over 5 years. Year to date, the return stands at a 21.8% decline, which can change how you think about both upside and risk. Recent coverage has focused on First Solar as part of ongoing interest in US-listed solar and...
NYSE:AXTA
NYSE:AXTAChemicals

Assessing Axalta Coating Systems (AXTA) Valuation After Softer Earnings And Flat Near‑Term Growth Outlook

Axalta Coating Systems (AXTA) shares have been reacting to fresh first quarter results, with sales of US$1,254 million and net income of US$90 million, along with guidance calling for flat second quarter net sales growth. See our latest analysis for Axalta Coating Systems. The first quarter update and cautious outlook appear to be weighing on sentiment, with Axalta Coating Systems’ recent 9.34% 1 month share price return still sitting against a weaker 1 year total shareholder return of...
NYSE:DRD
NYSE:DRDMetals and Mining

DRDGOLD (DRD) Is Up 5.2% After Debt-Free Growth And Lower Costs Is The Bull Case Changing?

DRDGOLD recently reported a stronger quarter to 31 March 2026, with higher revenue, increased gold production, improved yields and lower cash operating costs per kilogram. An interesting aspect of the update is that DRDGOLD continues to fund its growth projects without taking on debt, underscoring a disciplined capital approach. Next, we’ll examine how DRDGOLD’s combination of higher production and reduced cash operating costs could influence the company’s broader investment narrative. Find...
NYSE:MRP
NYSE:MRPSpecialized REITs

Millrose Properties (MRP) Is Down 12.3% After Surging Q1 Revenue And Net Income Report

Millrose Properties, Inc. has reported past first-quarter 2026 results, with revenue rising to US$194.93 million and net income to US$122.88 million, both significantly higher than the same period a year earlier. The sharp increase in revenue relative to the prior year's US$82.70 million highlights how much more transaction activity Millrose is now channeling through its land banking model. We will now examine how this sharp jump in quarterly revenue and net income affects Millrose...
NasdaqGS:EXC
NasdaqGS:EXCElectric Utilities

Is It Time To Reassess Exelon (EXC) After Recent Share Price Weakness?

Investors may be assessing whether Exelon at around US$44.41 is offering fair value today, or if the current price is mispricing the long term story. The stock has slipped 3.4% over the last 7 days and 9.5% over the last 30 days, while the 1 year return sits at 2.0% and the 5 year return at 65.7%. Recent attention on Exelon has centered on its role as a large regulated utility. Investors are watching how its business mix and capital plans fit into long term energy and grid needs. This...
NasdaqGS:LFUS
NasdaqGS:LFUSElectronic

Littelfuse (LFUS) Is Up 9.3% After Q1 Beat And Basler Outperformance Has The Bull Case Changed?

In early May 2026, Littelfuse reported first-quarter 2026 results showing sales rising to US$656.97 million and net income to US$75.15 million, with earnings per share roughly doubling from a year earlier. Management highlighted that the Basler acquisition outperformed initial expectations and, alongside broad-based demand across electronics, transportation, and industrial markets, is supporting margin expansion and a confident outlook for further acquisitions. With Q1 results beating...
NasdaqGS:CAI
NasdaqGS:CAIBiotechs

Is It Time To Reconsider Caris Life Sciences (CAI) After 26.5% Year To Date Decline?

If you are trying to work out whether Caris Life Sciences at around US$19.84 is attractively priced or not, you will want a clear view of what that tag really reflects. The stock has recently shown mixed momentum, with a 4.4% return over the last 7 days and 5.8% over the last month, while the year to date return stands at a 26.5% decline. Recent headlines around Caris Life Sciences have focused on its role in precision medicine and diagnostics, alongside ongoing attention to how it funds and...
NasdaqGS:INTC
NasdaqGS:INTCSemiconductor

Intel Gains U.S. Approval To Deepen SambaNova AI Collaboration

U.S. regulators have cleared Intel to increase its investment in AI chip developer SambaNova. The approval allows Intel to deepen its collaboration with SambaNova across generative AI chip and systems development. This clearance marks a new step in Intel's effort to build a broader position in advanced AI workloads beyond traditional CPUs. Intel, NasdaqGS:INTC, is drawing attention as it leans further into AI alongside its established CPU and foundry activities. The stock last closed at...
NYSE:BSX
NYSE:BSXMedical Equipment

Boston Scientific Governance Shift Raises Questions On Investor Influence

Boston Scientific (NYSE:BSX) stockholders approved the removal of supermajority voting requirements at a recent shareholder meeting. Shareholders also adopted officer exculpation protections and approved new shares for the Employee Stock Purchase Plan. Proposals to allow shareholders to call special meetings and other changes to shareholder rights were put forward but did not pass. Boston Scientific enters these governance changes with its stock at $56.57 and a mixed return profile. The...